Top

Published in:

Open Access 16-06-2023 | Type 2 Diabetes | Review

Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease

Authors: Tomasz Klupa, Leszek Czupryniak, Grzegorz Dzida, Piotr Fichna, Przemyslawa Jarosz-Chobot, Janusz Gumprecht, Malgorzata Mysliwiec, Agnieszka Szadkowska, Dorota Bomba-Opon, Krzysztof Czajkowski, Maciej T. Malecki, Dorota A. Zozulinska-Ziolkiewicz

Published in: Diabetes Therapy | Issue 8/2023

Abstract

Application of continuous glucose monitoring (CGM) has moved diabetes care from a reactive to a proactive process, in which a person with diabetes can prevent episodes of hypoglycemia or hyperglycemia, rather than taking action only once low and high glucose are detected. Consequently, CGM devices are now seen as the standard of care for people with type 1 diabetes mellitus (T1DM). Evidence now supports the use of CGM in people with type 2 diabetes mellitus (T2DM) on any treatment regimen, not just for those on insulin therapy. Expanding the application of CGM to include all people with T1DM or T2DM can support effective intensification of therapies to reduce glucose exposure and lower the risk of complications and hospital admissions, which are associated with high healthcare costs. All of this can be achieved while minimizing the risk of hypoglycemia and improving quality of life for people with diabetes. Wider application of CGM can also bring considerable benefits for women with diabetes during pregnancy and their children, as well as providing support for acute care of hospital inpatients who experience the adverse effects of hyperglycemia following admission and surgical procedures, as a consequence of treatment-related insulin resistance or reduced insulin secretion. By tailoring the application of CGM for daily or intermittent use, depending on the patient profile and their needs, one can ensure the cost-effectiveness of CGM in each setting. In this article we discuss the evidence-based benefits of expanding the use of CGM technology to include all people with diabetes, along with a diverse population of people with non-diabetic glycemic dysregulation.

Available only for authorised users

Freckmann G, Pleus S, Grady M, Setford S, Levy B. Measures of accuracy for continuous glucose monitoring and blood glucose monitoring devices. J Diabetes Sci Technol. 2019;13:575–83. https://doi.org/10.1177/1932296818812062.CrossRefPubMed

Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17:787–94. https://doi.org/10.1089/dia.2014.0378.CrossRefPubMedPubMedCentral

Ajjan RA, Cummings MH, Jennings P, Leelarathna L, Rayman G, Wilmot EG. Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: implications for clinical practice. Diabetes Vasc Dis Re. 2018;15:175–84. https://doi.org/10.1177/1479164118756240.CrossRef

Garg SK, Akturk HK. A new era in continuous glucose monitoring: food and drug administration creates a new category of factory-calibrated nonadjunctive, interoperable class II medical devices. Diabetes Technol Ther. 2018;20:391–4. https://doi.org/10.1089/dia.2018.0142.CrossRefPubMed

Bailey TS, Alva S. Landscape of continuous glucose monitoring (CGM) and integrated CGM: accuracy considerations. Diabetes Technol Ther. 2021;23:5–11. https://doi.org/10.1089/dia.2021.0236.CrossRef

Alva S, Bailey T, Brazg R, et al. Accuracy of a 14-day factory-calibrated continuous glucose monitoring system with advanced algorithm in pediatric and adult population with diabetes. J Diabetes Sci Technol. 2020. https://doi.org/10.1177/1932296820958754.CrossRefPubMedPubMedCentral

Joseph JI. Review of the long-term implantable senseonics continuous glucose monitoring system and other continuous glucose monitoring systems. J Diabetes Sci Technol. 2021;15:167–73. https://doi.org/10.1177/1932296820911919.CrossRefPubMed

Shah VN, Laffel LM, Wadwa RP, Garg SK. Performance of a factory-calibrated real-time continuous glucose monitoring system utilizing an automated sensor applicator. Diabetes Technol Ther. 2018;20:428–33. https://doi.org/10.1089/dia.2018.0143.CrossRefPubMedPubMedCentral

van der Linden J, Welsh JB, Walker TC. Sustainable use of a real-time continuous glucose monitoring system from 2018 to 2020. Diabetes Technol Ther. 2021;23:508–11. https://doi.org/10.1089/dia.2021.0014.CrossRefPubMed

10.

Raviteja KV, Kumar R, Dayal D, Sachdeva N. Clinical efficacy of professional continuous glucose monitoring in improving glycemic control among children with type 1 diabetes mellitus: an open-label randomized control trial. Sci Rep. 2019;9:6120. https://doi.org/10.1038/s41598-019-42555-6.CrossRefPubMedPubMedCentral

11.

Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317:379–87. https://doi.org/10.1001/jama.2016.19976.CrossRefPubMed

12.

Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care. 2017;40:538–45. https://doi.org/10.2337/dc16-2482.CrossRefPubMedPubMedCentral

13.

Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317:371–8. https://doi.org/10.1001/jama.2016.19975.CrossRefPubMed

14.

Šoupal J, Petruželková L, Grunberger G, et al. Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR study. Diabetes Care. 2019;43:37–43. https://doi.org/10.2337/dc19-0888.CrossRefPubMed

15.

Campbell FM, Murphy NP, Stewart C, Biester T, Kordonouri O. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes. 2018;19:1294–301. https://doi.org/10.1111/pedi.12735.CrossRefPubMed

16.

Leelarathna L, Evans ML, Neupane S, et al. Intermittently scanned continuous glucose monitoring for type 1 diabetes. New Engl J Med. 2022. https://doi.org/10.1056/nejmoa2205650.CrossRefPubMed

17.

Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55:3155–62. https://doi.org/10.1007/s00125-012-2708-9.CrossRefPubMedPubMedCentral

18.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care. 2010;33:17–22. https://doi.org/10.2337/dc09-1502.CrossRef

19.

Martens T, Beck RW, Bailey R, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin. JAMA. 2021;325:2262–72. https://doi.org/10.1001/jama.2021.7444.CrossRefPubMed

20.

Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections. Ann Intern Med. 2017;167:365. https://doi.org/10.7326/m16-2855.CrossRefPubMed

21.

Wright EE, Kerr MSD, Reyes IJ, Nabutovsky Y, Miller E. Use of flash continuous glucose monitoring is associated with A1C reduction in people with type 2 diabetes treated with basal insulin or noninsulin therapy. Diabetes Spectr. 2021;34:184–9. https://doi.org/10.2337/ds20-0069.CrossRefPubMedPubMedCentral

22.

Wada E, Onoue T, Kobayashi T, et al. Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care. 2020;8:e001115. https://doi.org/10.1136/bmjdrc-2019-001115.CrossRefPubMedPubMedCentral

23.

Riddlesworth T, Price D, Cohen N, Beck RW. Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections. Diabetes Ther. 2017;8:947–51. https://doi.org/10.1007/s13300-017-0281-4.CrossRefPubMedPubMedCentral

24.

Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254–63. https://doi.org/10.1016/s0140-6736(16)31535-5.CrossRefPubMed

25.

Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline J-P, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter open-label randomized controlled trial. Diabetes Ther. 2017;8:55–73. https://doi.org/10.1007/s13300-016-0223-6.CrossRefPubMed

26.

Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study. Diabetes Care. 2022;45:750–3. https://doi.org/10.2337/dc21-2004.CrossRefPubMed

27.

Evans M, Welsh Z, Seibold A. Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 months: a meta-analysis of 75 real-world observational studies. Diabetes Ther. 2022. https://doi.org/10.1007/s13300-022-01253-9.CrossRefPubMedPubMedCentral

28.

Agiostratidou G, Anhalt H, Ball D, et al. Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017;40:1622–30. https://doi.org/10.2337/dc17-1624.

29.

Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40:1631–40. https://doi.org/10.2337/dc17-1600.CrossRefPubMedPubMedCentral

30.

Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019. https://doi.org/10.2337/dci19-0028.CrossRefPubMedPubMedCentral

31.

Beck RW, Bergenstal RM. Continuous glucose monitoring for type 2 diabetes: how does it compare with type 1 diabetes? Diabetes Technol Ther. 2022;24:153–6. https://doi.org/10.1089/dia.2021.0374.CrossRefPubMed

32.

Bergenstal RM, Mullen DM, Strock E, Johnson ML, Xi MX. Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes. J Diabetes Complicat. 2022;36: 108106. https://doi.org/10.1016/j.jdiacomp.2021.108106.CrossRef

33.

Díez-Fernández A, Rodríguez-Huerta MD, Mirón-González R, Laredo-Aguilera JA, Martín-Espinosa NM. Flash glucose monitoring and patient satisfaction: a meta-review of systematic reviews. Int J Environ Res Pu. 2021;18:3123. https://doi.org/10.3390/ijerph18063123.CrossRef

34.

Gilbert TR, Noar A, Blalock O, Polonsky WH. Change in hemoglobin A1c and quality of life with real-time continuous glucose monitoring use by people with insulin-treated diabetes in the landmark study. Diabetes Technol Ther. 2021;23:35–9. https://doi.org/10.1089/dia.2020.0666.CrossRef

35.

Polonsky WH, Hessler D, Ruedy KJ, Beck RW. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the diamond randomized clinical trial. Diabetes Care. 2017;40:170. https://doi.org/10.2337/dc17-0133.CrossRef

36.

Charleer S, Mathieu C, Nobels F, et al. Effect of continuous glucose monitoring on glycemic control, acute admissions, and quality of life: a real-world study. J Clin Endocrinol Metab. 2018;103:1224–32. https://doi.org/10.1210/jc.2017-02498.CrossRefPubMed

37.

Charleer S, Block CD, Huffel LV, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care. 2020;43:389–97. https://doi.org/10.2337/dc19-1610.CrossRefPubMed

38.

Roussel R, Riveline J-P, Vicaut E, et al. Important drop rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the RELIEF study. Diabetes Care. 2021. https://doi.org/10.2337/dc20-1690.CrossRefPubMedPubMedCentral

39.

Riveline J-P, Roussel R, Vicaut E, et al. Reduced rate of acute diabetes events with flash glucose monitoring is sustained for two-years after initiation: extended outcomes from the RELIEF study. Diabetes Technol Ther. 2022. https://doi.org/10.1089/dia.2022.0085.CrossRefPubMedPubMedCentral

40.

Guerci B, Roussel R, Levrat-Guillen F, et al. Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre® system initiation in people with type 2 diabetes on basal insulin therapy in France. Diabetes Technol Ther. 2022. https://doi.org/10.1089/dia.2022.0271.CrossRefPubMed

41.

Barnard K, Crabtree V, Adolfsson P, et al. Impact of type 1 diabetes technology on family members/significant others of people with diabetes. J Diabetes Sci Technol. 2016;10:824–30. https://doi.org/10.1177/1932296816645365.CrossRefPubMedPubMedCentral

42.

Beasant L, Cullen F, Thomas E, et al. Flash glucose monitoring in young people with type 1 diabetes—a qualitative study of young people, parents and health professionals: ‘it makes life much easier.’ BMJ Open. 2023;13:e070477. https://doi.org/10.1136/bmjopen-2022-070477.CrossRefPubMedPubMedCentral

43.

Boucher SE, Aum SH, Crocket HR, et al. Exploring parental perspectives after commencement of flash glucose monitoring for type 1 diabetes in adolescents and young adults not meeting glycaemic targets: a qualitative study. Diabet Med. 2020;37:657–64. https://doi.org/10.1111/dme.14188.CrossRefPubMed

44.

Ng SM, Moore HS, Clemente MF, Pintus D, Soni A. Continuous glucose monitoring in children with type 1 diabetes improves well-being, alleviates worry and fear of hypoglycemia. Diabetes Technol Ther. 2019;21:133–7. https://doi.org/10.1089/dia.2018.0347.CrossRefPubMed

45.

Ng SM, Dearman S, Fisher M, Mushtaq T, Randell T. Paediatric society and hyperinsulinism charity national surveys on CGM access for patients with recurrent hypoglycaemia. J Endocr Soc. 2023;7:21. https://doi.org/10.1210/jendso/bvad021.CrossRef

46.

Mattishent K, Lane K, Salter C, et al. Continuous glucose monitoring in older people with diabetes and memory problems: a mixed-methods feasibility study in the UK. BMJ Open. 2019;9:e032037. https://doi.org/10.1136/bmjopen-2019-032037.CrossRefPubMedPubMedCentral

47.

Allen NA, Litchman ML, Chamberlain J, Grigorian EG, Iacob E, Berg CA. Continuous glucose monitoring data sharing in older adults with type 1 diabetes: pilot intervention study. JMIR Diabetes. 2022;7:e35687. https://doi.org/10.2196/35687.CrossRefPubMedPubMedCentral

48.

Polonsky WH, Fortmann AL. Impact of real-time CGM data sharing on quality of life in the caregivers of adults and children with type 1 diabetes. J Diabetes Sci Technol. 2020. https://doi.org/10.1177/1932296820978423.CrossRefPubMedPubMedCentral

49.

Battelino T, Alexander CM, Amiel SA, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 2022. https://doi.org/10.1016/s2213-8587(22)00319-9.CrossRefPubMed

50.

Mensh BD, Wisniewski NA, Neil BM, Burnett DR. Susceptibility of interstitial continuous glucose monitor performance to sleeping position. J Diabetes Sci Technol. 2013;7:863–70. https://doi.org/10.1177/193229681300700408.CrossRefPubMedPubMedCentral

51.

Schabert J, Browne JL, Mosely K, Speight J. Social stigma in diabetes: a framework to understand a growing problem for an increasing epidemic. Patient. 2013;6:1–10. https://doi.org/10.1007/s40271-012-0001-0.CrossRefPubMed

52.

FreeStyle Libre for glucose monitoring. Medtech innovation briefing [MIB110] 2017.

53.

Type 1 diabetes in adults: diagnosis and management NICE guideline Published: 26 August 2015. Last updated: 17 August 2022. https://www.nice.org.uk/guidance/ng17.

54.

Type 2 diabetes in adults: management NICE guideline. Published: 2 December 2015. Last updated: 29 June 2022. https://www.nice.org.uk/guidance/ng28.

55.

Diabetes (type 1 and type 2) in children and young people: diagnosis and management NICE guideline. Published: 1 August 2015. Last updated: 11 May 2023. https://www.nice.org.uk/guidance/ng18.

56.

American Diabetes Association. 7. Diabetes Technology: Standards of Medical Care in Diabetes—2019. Diabetes Care 2018;42:71–80. https://doi.org/10.2337/dc19-s007.

57.

American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 7. Diabetes Technology: Standards of Medical Care in Diabetes—2022. Diabetes Care 2021;45:S97–112. https://doi.org/10.2337/dc22-s007.

58.

Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44:2589–625. https://doi.org/10.2337/dci21-0043.CrossRefPubMed

59.

Tauschmann M, Forlenza G, Hood K, et al. ISPAD clinical practice consensus guidelines 2022: diabetes technologies: glucose monitoring. Pediatr Diabetes. 2022;23:1390–405. https://doi.org/10.1111/pedi.13451.CrossRefPubMedPubMedCentral

60.

Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. Pediatr Diabetes. 2022;23:1270–6. https://doi.org/10.1111/pedi.13455.CrossRefPubMedPubMedCentral

61.

Virmani A, Brink SJ, Middlehurst A, et al. ISPAD Clinical Practice Consensus Guidelines 2022: management of the child, adolescent, and young adult with diabetes in limited resource settings. Pediatr Diabetes. 2022;23:1529–51. https://doi.org/10.1111/pedi.13456.CrossRefPubMed

62.

Besser REJ, Bell KJ, Couper JJ, et al. Stages of type 1 diabetes in children and adolescents. Pediatr Diabetes. 2022. https://doi.org/10.1111/pedi.13410.CrossRefPubMed

63.

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022. https://doi.org/10.1007/s00125-022-05787-2.CrossRefPubMedPubMedCentral

64.

Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract. 2021;27:505–37. https://doi.org/10.1016/j.eprac.2021.04.008.CrossRefPubMed

65.

Virdi N. Response to American Association of clinical endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract. 2021;27:1062. https://doi.org/10.1016/j.eprac.2021.07.006.CrossRefPubMed

66.

Kong APK, Lim S, Yoo SH, et al. Asia-Pacific consensus recommendations for application of continuous glucose monitoring in diabetes management. Diabetes Res Clin Pract. 2023. https://doi.org/10.1016/j.diabres.2023.110718.CrossRefPubMed

67.

JDRF CGM Study Group. JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods. Diabetes Technol Ther. 2008;10:310–21. https://doi.org/10.1089/dia.2007.0302.CrossRef

68.

Ziegler R, von Sengbusch S, Kröger J, et al. Therapy adjustments based on trend arrows using continuous glucose monitoring systems. J Diabetes Sci Technol. 2019. https://doi.org/10.1177/1932296818822539.CrossRefPubMedPubMedCentral

69.

Akram K, Pedersen-Bjergaard U, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey. J Diabetes Complicat. 2006;20:402–8. https://doi.org/10.1016/j.jdiacomp.2005.08.005.CrossRef

70.

Carlson AL, Daniel TD, DeSantis A, et al. Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis. BMJ Open Diabetes Res Care. 2022;10:e002590. https://doi.org/10.1136/bmjdrc-2021-002590.CrossRefPubMedPubMedCentral

71.

Miller E, Kerr MSD, Roberts GJ, Nabutovsky Y, Wright E. Flash CGM associated with event reduction in nonintensive diabetes therapy. Am J Manag Care. 2021;27:372–7. https://doi.org/10.37765/ajmc.2021.88780.CrossRef

72.

Ziegler R, Heinemann L, Freckmann G, Schnell O, Hinzmann R, Kulzer B. Intermittent use of continuous glucose monitoring: expanding the clinical value of CGM. J Diabetes Sci Technol. 2021;15:684–94. https://doi.org/10.1177/1932296820905577.CrossRefPubMed

73.

Taylor PJ, Thompson CH, Brinkworth GD. Effectiveness and acceptability of continuous glucose monitoring for type 2 diabetes management: a narrative review. J Diabetes Invest. 2018;9:713–25. https://doi.org/10.1111/jdi.12807.CrossRef

74.

Price DA, Deng Q, Kipnes M, Beck SE. Episodic real-time CGM use in adults with type 2 diabetes: results of a pilot randomized controlled trial. Diabetes Ther. 2021;12:2089–99. https://doi.org/10.1007/s13300-021-01086-y.CrossRefPubMedPubMedCentral

75.

Moon SJ, Kim K, Lee WJ, Lee MY, Vigersky R, Park C. Efficacy of intermittent short-term use of a real-time continuous glucose monitoring system in non-insulin-treated patients with type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2022. https://doi.org/10.1111/dom.14852.CrossRefPubMed

76.

Allen NA, Fain JA, Braun B, Chipkin SR. Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: a randomized clinical trial. Diabetes Res Clin Pract. 2008;80:371–9. https://doi.org/10.1016/j.diabres.2008.01.006.CrossRefPubMedPubMedCentral

77.

Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycemia in type 2 diabetes—more common than you think. J Diabetes Sci Technol. 2015;9:999–1005. https://doi.org/10.1177/1932296815581052.CrossRefPubMedPubMedCentral

78.

Choudhary P, Portu S, Delbaere A, Lyon J, Pickup JC. A modelling study of the budget impact of improved glycaemic control in adults with type 1 diabetes in the UK. Diabetic Med. 2019;36:988–94. https://doi.org/10.1111/dme.13924.CrossRefPubMed

79.

Rotondi MA, Wong O, Riddell M, Perkins B. Population-level impact and cost-effectiveness of continuous glucose monitoring and intermittently scanned continuous glucose monitoring technologies for adults with type 1 diabetes in Canada: a modeling study. Diabetes Care. 2022. https://doi.org/10.2337/dc21-2341.CrossRefPubMedPubMedCentral

80.

Roze S, Isitt JJ, Smith-Palmer J, et al. Long-term cost-effectiveness the Dexcom G6 real-time continuous glucose monitoring system compared with self-monitoring of blood glucose in people with type 1 diabetes in France. Diabetes Ther. 2021;12:235–46. https://doi.org/10.1007/s13300-020-00959-y.CrossRefPubMed

81.

Roze S, Isitt J, Smith-Palmer J, Javanbakht M, Lynch P. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring versus self-monitoring of blood glucose in patients with type 1 diabetes in the UK. Diabetes Care. 2020;43:2411–7. https://doi.org/10.2337/dc19-2213.CrossRefPubMed

82.

Fonda SJ, Graham C, Munakata J, Powers JM, Price D, Vigersky RA. The cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) in type 2 diabetes. J Diabetes Sci Technol. 2016;10:898–904. https://doi.org/10.1177/1932296816628547.CrossRefPubMedPubMedCentral

83.

Sierra JA, Shah M, Gill MS, et al. Clinical and economic benefits of professional CGM among people with type 2 diabetes in the United States: analysis of claims and lab data. J Med Econ. 2018;21:225–30. https://doi.org/10.1080/13696998.2017.1390474.CrossRefPubMed

84.

Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care. 2019. https://doi.org/10.2337/dc18-0166.CrossRefPubMed

85.

Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361–9. https://doi.org/10.1016/s2213-8587(18)30051-2.CrossRefPubMed

86.

Hall H, Perelman D, Breschi A, et al. Glucotypes reveal new patterns of glucose dysregulation. Plos Biol. 2018;16:e2005143. https://doi.org/10.1371/journal.pbio.2005143.CrossRefPubMedPubMedCentral

87.

Safford MM, Shewchuk R, Qu H, et al. Reasons for not intensifying medications: differentiating “clinical inertia” from appropriate care. J Gen Intern Med. 2007;22:1648–55. https://doi.org/10.1007/s11606-007-0433-8.CrossRefPubMedPubMedCentral

88.

Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia in intensifying therapy among people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016. https://doi.org/10.1111/dom.12626.CrossRefPubMedPubMedCentral

89.

Seidu S, Than T, Kar D, et al. Therapeutic inertia amongst general practitioners with interest in diabetes. Prim Care Diabetes. 2018;12:87–91. https://doi.org/10.1016/j.pcd.2017.09.001.CrossRefPubMed

90.

Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American Diabetes Association’s standards of medical care in diabetes clinical guideline. Ann Intern Med. 2020;173:813–21. https://doi.org/10.7326/m20-2470.CrossRefPubMed

91.

Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. 2018;20:427–37. https://doi.org/10.1111/dom.13088.CrossRefPubMed

92.

Kaewbut P, Kosachunhanun N, Phrommintikul A, Chinwong D, Hall JJ, Chinwong S. Time to treatment intensification to reduce diabetes-related complications: a post hoc study. Healthcare (Basel). 2022;10:1673. https://doi.org/10.3390/healthcare10091673.CrossRefPubMed

93.

Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100. https://doi.org/10.1186/s12933-015-0260-x.CrossRefPubMedPubMedCentral

94.

Bain SC, Hansen BB, Hunt B, Chubb B, Valentine WJ. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. J Med Econ. 2019;23:1–1. https://doi.org/10.1080/13696998.2019.1645018.CrossRef

95.

Tsotra F, Kappel M, Peristeris P, et al. The societal impact of early intensified treatment in patients with type 2 diabetes mellitus. J Comp Effect Res. 2022. https://doi.org/10.2217/cer-2022-0110.CrossRef

96.

Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care. 2005;28:2543–5. https://doi.org/10.2337/diacare.28.10.2543.CrossRefPubMed

97.

Harris S, Levrat-Guillen F. Use of the FreeStyle Libre® system in diabetes treatment for people with T2D: results from a retrospective cohort study using Canadian private payer claims database. Diabetes Obesity Metab. 2023:25(6):1704–13.

98.

Simonson GD, Bergenstal RM, Johnson ML, Davidson JL, Martens TW. Effect of professional CGM (pCGM) on glucose management in type 2 diabetes patients in primary care. J Diabetes Sci Technol. 2021;15:539–45. https://doi.org/10.1177/1932296821998724.CrossRefPubMedPubMedCentral

99.

Sherrill CH, Houpt CT, Dixon EM, Richter SJ. Effect of pharmacist-driven professional continuous glucose monitoring in adults with uncontrolled diabetes. J Manag Care Spec. 2020;26:600–9. https://doi.org/10.18553/jmcp.2020.26.5.600.

100.

Wallace T, Heath J, Koebbel C. The impact of flash glucose monitoring on adults with type 1 diabetes’ eating habits and relationship with food. Diabetes Res Clin Pract. 2023;196:110230. https://doi.org/10.1016/j.diabres.2022.110230.CrossRefPubMed

101.

Polonsky WH, Fortmann AL, Soriano EC, Guzman SJ, Funnell MM. The AH-HA! project: transforming group diabetes self-management education through the addition of flash glucose monitoring. Diabetes Technol Ther. 2022. https://doi.org/10.1089/dia.2022.0419.CrossRefPubMedPubMedCentral

102.

Rivera-Ávila DA, Esquivel-Lu AI, Salazar-Lozano CR, Jones K, Doubova SV. The effects of professional continuous glucose monitoring as an adjuvant educational tool for improving glycemic control in patients with type 2 diabetes. BMC Endocr Disord. 2021;21:79. https://doi.org/10.1186/s12902-021-00742-5.CrossRefPubMedPubMedCentral

103.

Oser TK, Litchman ML, Allen NA, et al. Personal continuous glucose monitoring use among adults with type 2 diabetes: clinical efficacy and economic impacts. Curr Diabetes Rep. 2021;21:49. https://doi.org/10.1007/s11892-021-01408-1.CrossRef

104.

Bergenstal RM, Kerr MSD, Roberts GJ, Souto D, Nabutovsky Y, Hirsch IB. Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes. J Endocr Soc. 2021;5:13. https://doi.org/10.1210/jendso/bvab013.CrossRef

105.

FreeStyle Libre 2 Flash Glucose Monitoring System. Haute Autorite Sante 2020.

106.

Miao R, Wei W, Baser O, Xie L. Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine. Patient Prefer Adher. 2013;7:951–60. https://doi.org/10.2147/ppa.s49287.CrossRef

107.

Roussel R, Detournay B, Boultif Z, Bahloul A, Teissier C, Charbonnel B. Persistence with basal insulin and frequency of hypoglycemia requiring hospitalization in patients with type 2 diabetes. Diabetes Ther. 2020;11:1861–72. https://doi.org/10.1007/s13300-020-00874-2.CrossRefPubMedPubMedCentral

108.

Idris I, Gulati K, Perez-Nieves M, et al. Associated factors that influenced persistence with basal analog insulin therapy among people with type 2 diabetes: an exploratory analysis from a UK real-world sample. Prim Care Diabetes. 2019;13:106–12. https://doi.org/10.1016/j.pcd.2018.09.002.CrossRefPubMed

109.

Aleppo G, Beck RW, Bailey R, et al. The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin. Diabetes Care. 2021;44:2729–37. https://doi.org/10.2337/dc21-1304.CrossRefPubMedPubMedCentral

110.

Elliott T, Beca S, Beharry R, Tsoukas MA, Zarruk A, Abitbol A. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: a retrospective real-world chart review study. Diabetes Vasc Dis Re. 2021;18:14791641211021374. https://doi.org/10.1177/14791641211021374.CrossRef

111.

Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32:1626–31. https://doi.org/10.2337/dc09-0586.CrossRefPubMedPubMedCentral

112.

Alves C, Della-Manna T, Albuquerque CTM. Cystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment. J Pediatr Endocrinol Metab. 2020;33:835–43. https://doi.org/10.1515/jpem-2019-0484.CrossRefPubMed

113.

Pozo L, Bello F, Mendez Y, Surani S. Cystic fibrosis-related diabetes: the unmet need. World J Diabetes. 2020;11:213–7. https://doi.org/10.4239/wjd.v11.i6.213.CrossRefPubMedPubMedCentral

114.

Chamnan P, Shine BSF, Haworth CS, Bilton D, Adler AI. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care. 2010;33:311–6. https://doi.org/10.2337/dc09-1215.CrossRefPubMed

115.

Kumar S, Pallin M, Soldatos G, Teede H. Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic fibrosis: a systematic review. J Clin Transl Endocrinol. 2022;30:100305. https://doi.org/10.1016/j.jcte.2022.100305.CrossRefPubMedPubMedCentral

116.

Zorron M, Marson FAL, Morcillo AM, et al. Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome? J Bras Pneumol 2022;48:202. https://doi.org/10.36416/1806-3756/e20210307.

117.

Scully KJ, Sherwood JS, Martin K, et al. Continuous glucose monitoring and HbA1c in cystic fibrosis: clinical correlations and implications for CFRD diagnosis. J Clin Endocrinol Metab. 2021;107:e1444–54. https://doi.org/10.1210/clinem/dgab857.CrossRefPubMedCentral

118.

Kumar S, Soldatos G, Ranasinha S, Teede H, Pallin M. Continuous glucose monitoring versus self-monitoring of blood glucose in the management of cystic fibrosis related diabetes: a systematic review and meta-analysis. J Cyst Fibros. 2022. https://doi.org/10.1016/j.jcf.2022.07.013.CrossRefPubMed

119.

Gojsina B, Minic P, Todorovic S, Soldatovic I, Sovtic A. Continuous glucose monitoring as a valuable tool in the early detection of diabetes related to cystic fibrosis. Front Pediatr. 2021;9: 659728. https://doi.org/10.3389/fped.2021.659728.CrossRefPubMedPubMedCentral

120.

UK Cystic Fibrosis Registry. 2021 Annual Data Report. https://www.cysticfibrosis.org.uk/sites/default/files/2022-10/CFT_2021-Annual-Data-Report-WEB.pdf, 1.24 CF-related diabetes, 34.

121.

Grace T, Salyer J. Use of real-time continuous glucose monitoring improves glycemic control and other clinical outcomes in type 2 diabetes patients treated with less intensive therapy. Diabetes Technol Ther. 2022;24:26–31. https://doi.org/10.1089/dia.2021.0212.CrossRefPubMedPubMedCentral

122.

Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81. https://doi.org/10.1016/j.diabres.2018.02.023.CrossRefPubMed

123.

Bao S, Bailey R, Calhoun P, Beck RW. Effectiveness of continuous glucose monitoring in older adults with type 2 diabetes treated with basal insulin. Diabetes Technol Ther. 2022;24:299–306. https://doi.org/10.1089/dia.2021.0494.CrossRefPubMedPubMedCentral

124.

Guerci B, Levrat-Guillen F, Vicaut E, et al. Reduced acute diabetes events after FreeStyle Libre® system initiation in people 65 years or older with type 2 diabetes on intensive insulin therapy in France. Diabet Technol Ther. 2023. https://doi.org/10.1089/dia.2023.0034.CrossRef

125.

Munshi MN, Segal AR, Suhl E, et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med. 2011;171:362–4. https://doi.org/10.1001/archinternmed.2010.539.CrossRefPubMedPubMedCentral

126.

Lipska KJ, Warton EM, Huang ES, et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes. Diabetes Care. 2013;36:3535–42. https://doi.org/10.2337/dc13-0610.CrossRefPubMedPubMedCentral

127.

Meneilly GS, Tessier D. Diabetes in the elderly. Diabetic Med. 1995;12:949–60. https://doi.org/10.1111/j.1464-5491.1995.tb00405.x.CrossRefPubMed

128.

Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol Ser. 2001;56:M5-13. https://doi.org/10.1093/gerona/56.1.m5.CrossRef

129.

Schütt M, Fach E-M, Seufert J, et al. Multiple complications and frequent severe hypoglycaemia in ‘elderly’ and ‘old’ patients with type 1 diabetes. Diabetic Med. 2012;29:e176–9. https://doi.org/10.1111/j.1464-5491.2012.03681.x.CrossRefPubMed

130.

Wallander M, Axelsson KF, Nilsson AG, Lundh D, Lorentzon M. Type 2 diabetes and risk of hip fractures and non-skeletal fall injuries in the elderly: a study from the fractures and fall injuries in the elderly cohort (FRAILCO). J Bone Miner Res. 2017;32:449–60. https://doi.org/10.1002/jbmr.3002.CrossRefPubMed

131.

Mattishent K, Richardson K, Dhatariya K, Savva GM, Fox C, Loke YK. The effects of hypoglycaemia and dementia on cardiovascular events, falls and fractures and all-cause mortality in older individuals: a retrospective cohort study. Diabetes Obes Metab. 2019;21:2076–85. https://doi.org/10.1111/dom.13769.CrossRefPubMed

132.

Mattishent K, Loke YK. Is avoidance of hypoglycaemia a better target than HbA1C in older people with diabetes? Brit J Clin Pharmaco. 2021;87:9–11. https://doi.org/10.1111/bcp.14517.CrossRef

133.

Kosjerina V, Carstensen B, Jørgensen ME, et al. Discontinuation of diabetes medication in the 10 years before death in Denmark: a register-based study. Lancet Heal Longev. 2021;2:e561–70. https://doi.org/10.1016/s2666-7568(21)00170-7.CrossRef

134.

Hart HE, Ditzel K, Rutten GE, et al. De-intensification of blood glucose lowering medication in people identified as being over-treated: a mixed methods study. Patient Prefer Adher. 2019;13:1775–83. https://doi.org/10.2147/ppa.s208947.CrossRef

135.

Selvin E, Wang D, Tang O, Minotti M, Echouffo-Tcheugui JB, Coresh J. Glucose patterns in very old adults: a pilot study in a community-based population. Diabetes Technol Ther. 2021;23:737–44. https://doi.org/10.1089/dia.2021.0156.CrossRefPubMedPubMedCentral

136.

Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dementia. 2011;7:280–92. https://doi.org/10.1016/j.jalz.2011.03.003.CrossRefPubMed

137.

Athanasaki A, Melanis K, Tsantzali I, et al. Type 2 diabetes mellitus as a risk factor for Alzheimer’s disease: review and meta-analysis. Biomed. 2022;10:778. https://doi.org/10.3390/biomedicines10040778.CrossRef

138.

Sinclair A, Abdelhafiz A. Cognitive dysfunction in older adults with type 2 diabetes: links, risks, and clinical implications. Clin Geriatr Med. 2020;36:407–17. https://doi.org/10.1016/j.cger.2020.04.002.CrossRefPubMed

139.

Bordier L, Doucet J, Boudet J, Bauduceau B. Update on cognitive decline and dementia in elderly patients with diabetes. Diabetes Metab. 2014;40:331–7. https://doi.org/10.1016/j.diabet.2014.02.002.CrossRefPubMed

140.

Laiteerapong N, Karter AJ, Liu JY, et al. Correlates of quality of life in older adults with diabetes. Diabetes Care. 2011;34:1749–53. https://doi.org/10.2337/dc10-2424.CrossRefPubMedPubMedCentral

141.

Angeli F, Reboldi G, Poltronieri C, et al. Hyperglycemia in acute coronary syndromes: from mechanisms to prognostic implications. Ther Adv Cardiovasc Dis. 2015;9:412–24. https://doi.org/10.1177/1753944715594528.CrossRefPubMed

142.

Vedantam D, Poman DS, Motwani L, Asif N, Patel A, Anne KK. Stress-induced hyperglycemia: consequences and management. Cureus. 2022;14:e26714. https://doi.org/10.7759/cureus.26714.CrossRefPubMedPubMedCentral

143.

Marfella R, Federici M, Paolisso G. Editorial: hyperglycemia and coronary artery diseases: physio-pathological findings and therapeutic implications. Front Pharmacol. 2022;13: 901815. https://doi.org/10.3389/fphar.2022.901815.CrossRefPubMedPubMedCentral

144.

Malmberg K, Rydén L, Hamstent A, Herlitz J, Waldenström A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J. 1996;17:1337–44. https://doi.org/10.1093/oxfordjournals.eurheartj.a015067.CrossRefPubMed

145.

Ritsinger V, Malmberg K, Mårtensson A, Rydén L, Wedel H, Norhammar A. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. Lancet Diabetes Endocrinol. 2014;2:627–33. https://doi.org/10.1016/s2213-8587(14)70088-9.CrossRefPubMed

146.

Malmberg K, Rydén L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650–61. https://doi.org/10.1093/eurheartj/ehi199.CrossRefPubMed

147.

Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:4533. https://doi.org/10.1136/bmj.f4533.CrossRef

148.

Kissela BM, Khoury J, Kleindorfer D, et al. Epidemiology of ischemic stroke in patients with diabetes. Diabetes Care. 2005;28:355–9. https://doi.org/10.2337/diacare.28.2.355.CrossRefPubMed

149.

Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA stroke trial. Neurology. 2002;59:669–74. https://doi.org/10.1212/wnl.59.5.669.CrossRefPubMed

150.

Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients. Stroke. 2001;32:2426–32. https://doi.org/10.1161/hs1001.096194.CrossRefPubMed

151.

Krinock MJ, Singhal NS. Diabetes, stroke, and neuroresilience: looking beyond hyperglycemia. Ann N Y Acad Sci. 2021;1495:78–98. https://doi.org/10.1111/nyas.14583.CrossRefPubMed

152.

Rodgers ML, Fox E, Abdelhak T, et al. Care of the patient with acute ischemic stroke (Endovascular/Intensive Care Unit-Postinterventional Therapy): update to 2009 comprehensive nursing care scientific statement: a scientific statement from the American Heart Association. Stroke. 2021;52:e198-210. https://doi.org/10.1161/str.0000000000000358.CrossRefPubMed

153.

Yim C, Mansell K, Hussein N, Arnason T. Current cancer therapies and their influence on glucose control. World J Diabetes. 2021;12:1010–25. https://doi.org/10.4239/wjd.v12.i7.1010.CrossRefPubMedPubMedCentral

154.

Gerards MC, van der Velden DL, Baars JW, et al. Impact of hyperglycemia on the efficacy of chemotherapy—a systematic review of preclinical studies. Crit Rev Oncol Hemat. 2017;113:235–41. https://doi.org/10.1016/j.critrevonc.2017.03.007.CrossRef

155.

Egi M, Bellomo R, Stachowski E, et al. Blood glucose concentration and outcome of critical illness: the impact of diabetes. Crit Care Med. 2008;36:2249–55. https://doi.org/10.1097/ccm.0b013e318181039a.CrossRefPubMed

156.

Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, DeVries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med. 2010;38:838–42. https://doi.org/10.1097/ccm.0b013e3181cc4be9.CrossRefPubMed

157.

Yang J, Jia B, Qiao Y, Chen W, Qi X. Variations of blood glucose in cancer patients during chemotherapy. Niger J Clin Pract. 2016;19:704. https://doi.org/10.4103/1119-3077.187323.CrossRefPubMed

158.

Latham R, Lancaster AD, Covington JF, Pirolo JS, Thomas CS. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol. 2001;22:607–12. https://doi.org/10.1086/501830.CrossRefPubMed

159.

Martin ET, Kaye KS, Knott C, et al. Diabetes and risk of surgical site infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2016;37:88–99. https://doi.org/10.1017/ice.2015.249.CrossRefPubMed

160.

Buehler L, Fayfman M, Alexopoulos A-S, et al. The impact of hyperglycemia and obesity on hospitalization costs and clinical outcome in general surgery patients. J Diabetes Complicat. 2015;29:1177–82. https://doi.org/10.1016/j.jdiacomp.2015.07.027.CrossRef

161.

Ruedy KJ, Parkin CG, Riddlesworth TD, Graham C, DIAMOND Study Group. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol. 2017;11:1138–46. https://doi.org/10.1177/1932296817704445.CrossRefPubMedPubMedCentral

162.

Gomes V, Ferreira F, Guerra J, Bugalho MJ. New-onset diabetes after kidney transplantation: incidence and associated factors. World J Diabetes. 2018;9:132–7. https://doi.org/10.4239/wjd.v9.i7.132.CrossRefPubMedPubMedCentral

163.

Vest AR, Cherikh WS, Noreen SM, Stehlik J, Khush KK. New-onset diabetes mellitus after adult heart transplantation and the risk of renal dysfunction or mortality. Transplantation. 2022;106:178–87. https://doi.org/10.1097/tp.0000000000003647.CrossRefPubMed

164.

Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation. 2003;75:3–24. https://doi.org/10.1097/01.tp.0000069952.49242.3e.CrossRef

165.

Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV impact of post-transplant diabetes. Kidney Int. 2002;62:1440–6. https://doi.org/10.1111/j.1523-1755.2002.kid582.x.CrossRefPubMed

166.

Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2018;42: 181444. https://doi.org/10.2337/dc18-1444.CrossRef

167.

Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care. 2018;41: 181131. https://doi.org/10.2337/dc18-1131.CrossRef

168.

Sobngwi E, Ashuntantang G, Ndounia E, et al. Continuous interstitial glucose monitoring in non-diabetic subjects with end-stage renal disease undergoing maintenance haemodialysis. Diabetes Res Clin Pract. 2010;90:22–5. https://doi.org/10.1016/j.diabres.2010.06.001.CrossRefPubMed

169.

Joubert M, Fourmy C, Henri P, Ficheux M, Lobbedez T, Reznik Y. Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study. Diabetes Res Clin Pract. 2015;107:348–54. https://doi.org/10.1016/j.diabres.2015.01.026.CrossRefPubMed

170.

Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41:181581. https://doi.org/10.2337/dc18-1581.CrossRef

171.

Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE, Tuttle KR. Glycemic monitoring and management in advanced chronic kidney disease. Endocr Rev. 2020;41:756–74. https://doi.org/10.1210/endrev/bnaa017.CrossRefPubMedPubMedCentral

172.

Gomez-Peralta F, Choudhary P, Cosson E, Irace C, Rami-Merhar B, Seibold A. Understanding the clinical implications of differences between GMI and HbA1c. Diabetes Obes Metab. 2022. https://doi.org/10.1111/dom.14638.CrossRefPubMed

173.

Murphy HR, Howgate C, O’Keefe J, et al. Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study. Lancet Diabetes Endocrinol. 2021;9:153–64. https://doi.org/10.1016/s2213-8587(20)30406-x.CrossRefPubMed

174.

Evers IM, de Valk HW, Visser GHA. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ. 2004;328:915. https://doi.org/10.1136/bmj.38043.583160.ee.CrossRefPubMedPubMedCentral

175.

Dirar AM, Doupis J. Gestational diabetes from A to Z. World J Diabetes. 2017;8:489–511. https://doi.org/10.4239/wjd.v8.i12.489.CrossRef

176.

Shen S-Y, Žurauskienė J, Wei D-M, et al. Identification of maternal continuous glucose monitoring metrics related to newborn birth weight in pregnant women with gestational diabetes. Endocrine. 2021;74:290–9. https://doi.org/10.1007/s12020-021-02787-x.CrossRefPubMed

177.

Law GR, Alnaji A, Alrefaii L, et al. Suboptimal nocturnal glucose control is associated with large for gestational age in treated gestational diabetes mellitus. Diabetes Care. 2019;42:810–5. https://doi.org/10.2337/dc18-2212.CrossRefPubMed

178.

Gáborová M, Doničová V, Bačová I, et al. Glycaemic variability and risk factors of pregnant women with and without gestational diabetes mellitus measured by continuous glucose monitoring. Int J Environ Res Public Health. 2021;18:3402. https://doi.org/10.3390/ijerph18073402.CrossRefPubMedPubMedCentral

179.

Majewska A, Stanirowski PJ, Wielgoś M, Bomba-Opoń D. Efficacy of continuous glucose monitoring on glycaemic control in pregnant women with gestational diabetes mellitus—a systematic review. J Clin Med. 2022;11:2932. https://doi.org/10.3390/jcm11102932.CrossRefPubMedPubMedCentral

180.

García-Moreno RM, Benítez-Valderrama P, Barquiel B, et al. Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Diabet Med. 2022;39:e14703. https://doi.org/10.1111/dme.14703.CrossRefPubMed

181.

Harder T, Rodekamp E, Schellong K, Dudenhausen JW, Plagemann A. Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol. 2007;165:849–57. https://doi.org/10.1093/aje/kwk071.CrossRefPubMed

182.

Geserick M, Vogel M, Gausche R, et al. Acceleration of BMI in early childhood and risk of sustained obesity. New Engl J Med. 2018;379:1303–12. https://doi.org/10.1056/nejmoa1803527.CrossRefPubMed

183.

Oxman R, Roe AH, Jagdeesh U, Putman MS. Gestational and pregestational diabetes in pregnant women with cystic fibrosis. J Clin Transl Endocrinol. 2022;27: 100289. https://doi.org/10.1016/j.jcte.2021.100289.CrossRefPubMed

184.

Ashcroft A, Chapman S, Mackillop L. The outcome of pregnancy in women with cystic fibrosis: a UK population-based descriptive study. Bjog Int J Obstetrics Gynaecol. 2020;127:1696–703. https://doi.org/10.1111/1471-0528.16423.CrossRef

185.

Murphy HR, Rayman G, Duffield K, et al. Changes in the glycemic profiles of women with type 1 and type 2 diabetes during pregnancy. Diabetes Care. 2007;30:2785–91. https://doi.org/10.2337/dc07-0500.CrossRefPubMed

186.

Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390:2347–59. https://doi.org/10.1016/s0140-6736(17)32400-5.CrossRefPubMedPubMedCentral

187.

Scott EM, Murphy HR, Kristensen KH, et al. Continuous glucose monitoring metrics and birth weight: informing management of type 1 diabetes throughout pregnancy. Diabetes Care. 2022;45:1724–34. https://doi.org/10.2337/dc22-0078.CrossRefPubMed

188.

Kristensen K, Ögge LE, Sengpiel V, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. Diabetologia. 2019;62:1143–53. https://doi.org/10.1007/s00125-019-4850-0.CrossRefPubMedPubMedCentral

189.

Bartal MF, Cornthwaite JA, Ghafir D, et al. Time in range and pregnancy outcomes in people with diabetes using continuous glucose monitoring. Am J Perinat. 2022. https://doi.org/10.1055/a-1904-9279.CrossRef

190.

Dori-Dayan N, Cukierman-Yaffe T, Kedar N, et al. Maternal glucose variability during pregnancy & birthweight percentile in women with pre-gestational diabetes. Gynecol Endocrinol. 2021;37:1116–20. https://doi.org/10.1080/09513590.2021.1993814.CrossRefPubMed

191.

Lemaitre M, Faiz K, Baudoux F, Subtil D, Vambergue A. Intermittently scanned continuous glucose monitoring is associated with lower spontaneous abortion rate compared with conventional blood glucose monitoring in pregnant women with type 1 diabetes: an observational study. Diabetes Vasc Dis Res. 2022;19:14791641221136836. https://doi.org/10.1177/14791641221136837.CrossRef

192.

Majewska A, Stanirowski P, Wielgoś M, Bomba-Opoń D. Flash glucose monitoring in gestational diabetes mellitus: study protocol for a randomised controlled trial. BMJ Open. 2021;11:e041486. https://doi.org/10.1136/bmjopen-2020-041486.CrossRefPubMedPubMedCentral

193.

Choudhary P, Bellido V, Graner M, et al. The challenge of sustainable access to telemonitoring tools for people with diabetes in Europe: lessons from COVID-19 and beyond. Diabetes Ther. 2021;2:1–17. https://doi.org/10.1007/s13300-021-01132-9.CrossRef

194.

Commission E. Benchmarking deployment of eHealth among general practitioners. 2018.

195.

Danne T, Limbert C, Domingo MP, et al. Telemonitoring, telemedicine and time in range during the pandemic: paradigm change for diabetes risk management in the post-COVID future. Diabetes Ther. 2021;12:2289–310. https://doi.org/10.1007/s13300-021-01114-x.CrossRefPubMedPubMedCentral

196.

Silva-Tinoco R, de la Torre-Saldaña V. The imperious need for telemedicine for the care of diabetes during the COVID-19 pandemic. A comprehensive approach study. Gac Med Mex. 2021;157:309–12. https://doi.org/10.24875/gmm.m21000563.CrossRefPubMed

197.

Pogorzelska K, Marcinowicz L, Chlabicz S. A qualitative study of primary care physicians’ experiences with telemedicine during the COVID-19 pandemic in North-Eastern Poland. Int J Environ Res Public Health. 2023;20:1963. https://doi.org/10.3390/ijerph20031963.CrossRefPubMedPubMedCentral

198.

Poitras M-E, Poirier M-D, Couturier Y, et al. Chronic conditions patient’s perception of post-COVID-19 pandemic teleconsulting continuation in primary care clinics: a qualitative descriptive study. BMJ Open. 2022;12:e066871. https://doi.org/10.1136/bmjopen-2022-066871.CrossRefPubMed

Title: Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease
Authors: Tomasz Klupa
Leszek Czupryniak
Grzegorz Dzida
Piotr Fichna
Przemyslawa Jarosz-Chobot
Janusz Gumprecht
Malgorzata Mysliwiec
Agnieszka Szadkowska
Dorota Bomba-Opon
Krzysztof Czajkowski
Maciej T. Malecki
Dorota A. Zozulinska-Ziolkiewicz
Publication date: 16-06-2023
Publisher: Springer Healthcare
Keywords: Type 2 Diabetes
Gestational Diabetes
Type 1 Diabetes
Hyperglycemia
Diabetes Therapy
Endocrinology
Insulins
Insulins
Hypoglycemia
Published in: Diabetes Therapy / Issue 8/2023
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI: https://doi.org/10.1007/s13300-023-01431-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Continuous glucose monitoring device/© Dragoljub / stock.adobe.com (symbolic image with models), Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2023

Real-World User and Clinician Perspective and Experience with MiniMed™ 780G Advanced Hybrid Closed Loop System

Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study

Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels

Real-World Effects of Second-Generation Versus Earlier Intermediate/Basal Insulin Analogues on Rates of Hypoglycemia in Adults with Type 1 and 2 Diabetes (iNPHORM, US)

Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden

Circulating Cytokine Levels and Cardiovascular Disease Risk Profile in Young Adult Offspring of Women with Type 1 Diabetes

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage